GSK PLC closed 16.86% short of its 52-week high of £18.24, which the company reached on May 16th.

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 15.88% below its 52-week high of £18.24, which the company reached on May 16th.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

GSK plc (LON:GSK – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,444 ($18.73) and traded as high ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Ten small & medium-sized charities have been named as winners of the 2025 GSK IMPACT Awards for their work improving health ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.